Company Pleads Guilty To Felony Misbranding Of A Drug
Grant C. Jaquith, Temporary Acting United States Attorney for the Northern District of New York, and Mark Dragonetti, Special Agent-in-Charge of the Food and Drug Administration, Office of Criminal Investigations, New York Field Office, announced that The Plastic Surgery Group, LLP (TPSG) of Albany, New York, was sentenced and ordered to pay restitution in the amount of $106,686, and a fine of $200,000, in connection with TPSG's plea of guilty to one felony count of misbranding drugs, in violation of Title 21, United States Code, Sections 331(k), 352(i)(3), and 333(a)(2). TPSG was sentenced in Federal District Court in Albany, New York by District Judge Thomas J. McAvoy.
Additionally, Doctors William F. De Luca, Jr., Douglas M. Hargrave, Jeffrey L. Rockmore, Steven M. Lynch, And John D. Noonan, were sentenced to probation with community service, and ordered to pay restitution in the amount of $106,686, and a fine of $5,000. TPSG's practice administrator, Peter M. Slattery, and supervisory nurse Susan F. Knott, were also sentenced and ordered to pay restitution in the amount of $106,686, and fines in the amount of $1,000 and $500, respectively. All individual defendants were sentenced in connection with their guilty pleas to one misdemeanor count of misbranding drugs, in violation of Title 21, United States Code, Sections 331(k), 352(i)(3), and 333(a)(1), in United States District Court in Albany, New York by Magistrate Judge David R. Homer.
According to plea agreements, starting in approximately February 2004 and continuing to December 2004, defendant TPSG ceased using the FDA-approved BOTOX® and BOTOX® Cosmetic and began exclusively using a non-FDA approved TRI-toxin on its patients seeking treatments with Botulinum Toxin Type A for facial wrinkles. Five (5) physicians, whose professional corporations were partners of TPSG (the "treating physicians"), with the assistance of TPSG nurses, injected approximately one hundred and fifty (150) patients with the unapproved product.
View drug information on Botox Cosmetic.
Last relative articles:
- Allergan, Inc. Announces FDA Approval Of JUVEDERM R XC Dermal Filler Formulated With Lidocaine
- Surgical Safety Research Recieves 2010 HSR Impact Award
- Male Breast Reduction Fastest Growing Area Of Cosmetic Surgery In Britain Last Year
- Bariatric Surgery Can Be Safer Than Living With Obesity
- Nerve Graft Transplant Can Prove Successful In Eliminating Many Life-Threatening Pressure Ulcers
- BioTime Reports Results From Independent Hextend R Study
- First Fractional Laser FDA Cleared For Striae
- Two Studies Find Artefill R To Be A Long-Term Treatment Option For Facial Lipoatrophy
- University Of Florida Surgeons, Research Biologists Create Scale To Grade Shark Bite Severity
- Doctors Feel 'Choosing To Be Thinner In 2010 Could Be Bad For Your Health'
york, albany york, york field, york mark, york sentenced, york magistrate, investigations york, district york, york district